joint
work
group
establish
haematooncolog
subgroup
british
committe
standard
haematolog
british
societi
bone
marrow
transplant
uk
clinic
virolog
network
review
avail
literatur
made
recommend
diagnosi
manag
respiratori
viral
infect
patient
haematolog
malign
undergo
haematopoiet
stem
cell
transplant
guidelin
includ
recommend
diagnosi
prevent
treatment
respiratori
viral
infect
adult
children
suggest
recommend
primarili
intend
physician
practis
unit
kingdom
joint
work
group
establish
haematooncolog
subgroup
british
committe
standard
haematolog
british
societi
bone
marrow
transplant
uk
clinic
virolog
network
review
avail
literatur
made
recommend
diagnosi
manag
respiratori
viral
infect
patient
haematolog
malign
undergo
haematopoiet
stem
cell
transplant
guidelin
includ
recommend
diagnosi
prevent
treatment
respiratori
viral
infect
adult
children
suggest
recommend
primarili
intend
physician
practis
unit
kingdom
keyword
influenza
respiratori
syncyti
viru
metapneumoviru
parainfluenza
stem
cell
transplant
joint
work
group
establish
haematooncolog
subgroup
british
committe
standard
haematolog
bcsh
british
societi
blood
marrow
transplant
bsbmt
uk
clinic
virolog
network
review
avail
literatur
made
recommend
diagnosi
prevent
manag
common
respiratori
viral
infect
adult
children
undergo
treatment
haematolog
malign
haematopoiet
stem
cell
transplant
hsct
guidelin
focu
follow
respiratori
viral
infect
influenza
respiratori
syncyti
viru
rsv
human
metapneumoviru
hmpv
human
parainfluenza
viru
hpiv
human
rhinoviru
hrv
manag
adenoviru
opportunist
infect
notabl
cytomegaloviru
herp
simplex
viru
varicella
zoster
viru
may
involv
respiratori
tract
beyond
scope
manuscript
discuss
human
coronaviru
commun
acquir
respiratori
virus
includ
bocaviru
discuss
due
lack
avail
data
area
key
area
cover
guidelin
diagnosi
prevent
treatment
product
guidelin
involv
follow
step
use
follow
key
word
respiratori
viral
infect
stem
cell
transplant
chemotherapi
human
rhinoviru
hrv
human
metapneumoviru
hmpv
respiratori
syncyti
viru
rsv
human
parainfluenza
hpiv
influenza
diagnosi
prevent
treatment
report
major
confer
includ
american
societi
haematolog
european
bone
marrow
transplant
annual
meet
also
review
februari
use
keyword
develop
key
recommend
base
random
control
trial
evid
due
pauciti
random
studi
recommend
base
literatur
review
consensu
expert
opinion
grade
nomenclatur
use
evalu
level
evid
assess
strength
recommend
grade
criteria
specifi
bcsh
guidelin
pack
grade
work
group
websit
inform
avail
follow
websit
review
bcsh
committe
bsbmt
execut
committe
uk
clinic
virolog
network
uk
paediatr
bone
marrow
transplant
group
review
sound
board
british
societi
haematolog
bsh
allogen
transplant
centr
uk
strength
recommend
strong
grade
strong
recommend
grade
made
confid
benefit
outweigh
harm
burden
grade
recommend
appli
uniformli
patient
regard
recommend
weak
grade
magnitud
benefit
less
certain
weaker
grade
recommend
made
grade
recommend
requir
judici
applic
individu
patient
regard
suggest
qualiti
evid
grade
high
moder
b
low
c
put
context
use
consid
uncertainti
knowledg
whether
research
could
chang
know
certainti
high
research
unlik
chang
confid
estim
effect
current
evid
deriv
random
clinic
trial
without
import
limit
b
moder
research
may
well
import
impact
confid
estim
effect
may
chang
estim
current
evid
deriv
random
clinic
trial
import
limit
eg
inconsist
result
imprecisionwid
confid
interv
methodolog
flawseg
lack
blind
larg
loss
followup
failur
adher
intent
treat
analysi
strong
evid
observ
studi
case
seri
eg
larg
larg
consist
estim
magnitud
treatment
effect
demonstr
doserespons
gradient
c
low
research
like
import
impact
confid
estim
effect
like
chang
estim
current
evid
observ
studi
case
seri
opinion
respiratori
viral
infect
common
gener
popul
pose
particular
threat
patient
haematolog
malign
undergo
hsct
incid
infect
respiratori
virus
patient
undergo
haematolog
malign
hsct
like
reflect
incid
commun
whimbey
et
al
common
respiratori
virus
respect
serotyp
season
variat
incub
period
mode
transmiss
detail
tabl
public
health
england
nation
infect
servic
http
wwwgovukgovern
mani
patient
haematolog
malign
particularli
undergo
hsct
risk
progress
lower
respiratori
tract
infect
lrti
full
clinic
histori
examin
essenti
make
diagnosi
viral
respiratori
tract
diseas
chest
xray
computer
tomographi
ct
scan
may
help
confirm
exclud
presenc
lower
respiratori
tract
diseas
definit
upper
lower
respiratori
tract
infect
differ
report
purpos
guidelin
defin
follow
base
european
confer
infect
leukaemia
ecil
recommend
hirsch
et
al
gle
sputum
sampl
tracheal
aspir
bronchoalveolar
lavag
bal
sampl
collect
nasal
throat
swab
salin
throat
gargl
effect
diagnos
primari
viral
infect
children
use
polymeras
chain
reaction
pcr
blaschk
et
al
tunsjo
et
al
direct
immunofluoresc
antigen
detect
del
et
al
lower
sensit
ohrmalm
et
al
report
nonprimari
mild
infect
immunocompromis
patient
suggest
nasopharyng
aspir
nasal
wash
consid
possibl
like
aspir
wash
provid
consist
specimen
patient
symptom
sign
lrti
specimen
obtain
lower
respiratori
tract
possibl
sampl
might
obtain
induc
sputum
tracheal
aspir
bal
sampl
sampl
obtain
bal
also
test
copathogen
joo
et
al
viral
cultur
immunofluoresc
test
use
past
diagnosi
respiratori
virus
popul
supersed
molecular
diagnost
current
recommend
diagnosi
respiratori
viral
infect
made
quantit
nucleic
acid
amplif
test
naat
gener
refer
hereaft
pcr
clinician
abl
liais
virolog
laboratori
colleagu
regard
interpret
pcr
result
review
hirsch
et
al
panel
virus
includ
pcr
test
includ
parainfluenza
type
develop
molecular
test
may
allow
rapid
point
care
test
futur
would
optim
patient
popul
present
assay
haa
et
al
late
winter
earli
spring
haa
et
al
rang
haa
et
al
direct
close
contact
droplet
larg
particl
aerosol
saliva
haa
et
al
rhinoviru
picornavirida
rna
virusposit
sens
genu
rhinoviru
moor
et
al
speci
b
c
numer
subtyp
moor
et
al
season
lessler
et
al
contact
direct
via
fomit
aerosol
larg
small
particl
conjunctivalintranas
inocul
via
oral
rout
jacob
et
al
rsv
respiratori
syncyti
viru
hpiv
human
parainfluenza
hmpv
human
metapneumoviru
lrti
lower
respiratori
tract
infect
specif
immunocompromis
patient
avail
point
care
test
restrict
rang
lack
sensit
specif
routin
use
recommend
diagnosi
respiratori
viral
infect
made
polymeras
chain
reaction
pcr
test
recommend
diagnosi
upper
respiratori
tract
infect
made
upper
respiratori
tract
specimen
obtain
nasopharyng
aspir
wash
collect
nasal
throat
swab
recommend
diagnosi
lower
respiratori
tract
infect
made
lower
respiratori
tract
specimen
eg
bronchoalveolar
lavag
tracheal
aspir
induc
sputum
possibl
number
risk
factor
identifi
progress
lrti
mortal
similar
common
respiratori
virus
includ
neutropenia
lymphopenia
allogen
transplant
preengraft
earli
postengraft
graftversushost
diseas
presenc
copathogen
older
age
walsh
et
al
walsh
et
al
ljungman
et
al
ljungman
et
al
nichol
et
al
nichol
et
al
recommend
patient
assess
risk
factor
progress
lower
respiratori
tract
infect
increas
mortal
prior
decid
treatment
plan
vaccin
current
avail
rsv
hpiv
hrv
hmpv
infect
patient
household
contact
staff
encourag
receiv
influenza
vaccin
annual
basi
accord
nation
guidanc
green
book
public
health
england
postexposur
prophylaxi
may
option
immunosuppress
individu
close
contact
proven
influenza
influenzalik
ill
expos
person
effect
cover
vaccin
nation
institut
health
care
excel
nice
becom
immunosuppress
result
either
underli
diseas
condit
abl
treatment
use
hsct
post
exposur
prophylaxi
could
help
patient
receiv
vaccin
addit
could
help
situat
vaccin
administ
provid
protect
circul
strain
viru
patient
recent
receiv
rituximab
may
also
respond
vaccin
berglund
et
al
recommend
prophylaxi
updat
annual
avail
public
health
england
suggest
websit
review
directli
ensur
guidanc
date
http
wwwgovukgovernmentcollectionsseasonalinfluenzaguidancedataandanalysi
last
access
novemb
recommend
provid
health
protect
scotland
base
recommend
http
wwwhpsscotnhsukrespseasonalinfluenzaaspx
last
access
novemb
public
health
wale
also
follow
similar
recommend
http
last
access
juli
current
recommend
mg
oseltamivir
oral
daili
domin
influenza
strain
lower
risk
oseltamivir
resist
eg
recommend
provid
lower
dose
children
year
age
ideal
therapi
start
within
h
exposur
advic
specialist
inhal
zanamivir
mg
daili
adult
children
year
age
licens
children
year
altern
domin
influenza
strain
like
resist
oseltamivir
eg
ideal
therapi
start
within
h
last
contact
use
zanamivir
reli
abil
adult
child
effect
use
inhal
intraven
nebul
zanamivir
unlicens
avail
compassion
use
name
patient
basi
healthcar
worker
urti
lrti
symptom
avoid
contact
suscept
patient
possibl
appreci
might
alway
practic
hirsch
et
al
treatment
unit
measur
place
stop
spread
infect
may
mean
cohort
patient
screen
patient
event
outbreak
insuffici
evid
support
routin
screen
although
may
help
event
outbreak
respiratori
viral
infect
easili
transmit
person
person
patient
haematolog
malign
advis
avoid
contact
patient
respiratori
viral
infect
commun
possibl
hirsch
et
al
outpati
urti
lrti
symptom
isol
patient
clinic
ambulatori
care
facil
possibl
hirsch
et
al
recommend
patient
undergo
treatment
haematolog
malign
haematopoiet
stem
cell
transplant
well
staff
care
household
contact
receiv
influenza
vaccin
annual
basi
recommend
current
public
health
england
recommend
post
exposur
prophylaxi
influenza
infect
follow
recommend
allogen
transplant
patient
undergo
treatment
haematolog
malign
respiratori
tract
symptom
isol
haematooncolog
patient
outpati
set
possibl
suggest
screen
patient
may
consid
event
outbreak
respiratori
viral
infect
recommend
allogen
transplant
patient
undergo
treatment
haematolog
malign
respiratori
viral
infect
isol
side
room
neutral
air
pressur
antechamb
undergo
inpati
treatment
patient
respiratori
viral
infect
suscept
coinfect
organ
patient
activ
screen
treat
coexist
infect
patient
monitor
close
sign
respiratori
failur
includ
increas
respiratori
rate
hypoxia
earli
intervent
critic
care
team
consid
patient
progress
respiratori
failur
patient
receiv
corticosteroid
consider
given
taper
dose
possibl
infect
pneumocysti
jirovecii
exclud
respiratori
infect
develop
patient
taper
steroid
undertaken
recommend
patient
respiratori
virus
activ
screen
copathogen
includ
pneumocysti
jirovecii
recommend
patient
respiratori
virus
monitor
sign
respiratori
failur
critic
care
team
involv
requir
recommend
immunosuppress
reduc
possibl
patient
respiratori
virus
patient
urti
symptom
screen
prior
treatment
sequenti
infect
respiratori
viral
infect
may
progress
pneumonia
succeed
system
bacteri
fungal
infect
common
immunosuppress
patient
potenti
fatal
addit
presenc
viral
infect
includ
rhinoviru
prior
hsct
link
poorer
outcom
posthsct
campbel
et
al
therefor
patient
suspect
respiratori
viral
infect
care
assess
clinic
appropri
sampl
taken
purpos
diagnost
test
postpon
cytotox
therapi
hsct
hand
hygien
wear
protect
cloth
per
unit
polici
eg
apron
glove
mask
safe
dispos
oral
nasal
secret
cover
mouth
cough
sneez
isol
inpati
respiratori
symptom
neutral
pressur
room
isol
outpati
respiratori
symptom
possibl
advis
rel
visit
respiratori
symptom
symptom
resolv
must
consid
howev
pace
stage
underli
diseas
may
make
impract
casebycas
evalu
necessari
champlin
whimbey
peck
et
al
tomblyn
et
al
hirsch
et
al
recommend
patient
symptom
suggest
upper
lower
respiratori
tract
infect
screen
respiratori
viral
infect
prior
commenc
therapi
recommend
consider
given
delay
cytotox
therapi
haematopoiet
stem
cell
transplant
patient
activ
respiratori
viral
infect
although
limit
data
random
control
trial
util
correct
durat
use
licens
antivir
immunocompromis
individu
guidelin
clinic
report
avail
almost
observ
studi
hsct
highrisk
leukaemia
demonstr
clinic
benefit
antivir
therapi
compar
therapi
casper
et
al
choi
et
al
fraaij
et
al
ljungman
et
al
retrospect
studi
adult
patient
leukaemia
patient
receiv
neuraminidas
inhibitor
nai
patient
untreat
patient
treatment
group
die
patient
untreat
die
p
chemali
et
al
hsct
recipi
retrospect
studi
includ
adult
children
show
untreat
patient
develop
pneumonia
wherea
patient
treat
rimantadin
treat
oseltamivir
develop
pneumonia
ie
treat
patient
nichol
et
al
nai
form
mainstay
current
recommend
mechan
action
interfer
releas
influenza
viru
particl
infect
cell
prevent
spread
infect
cell
recommend
public
health
england
guidanc
follow
regard
treatment
influenza
http
wwwgovukgovernmentcollectionsseasonalinfluenzaguidancedataandanalysi
last
access
novemb
current
guidanc
recommend
oseltamivir
oral
mg
twice
daili
patient
year
age
dose
provid
younger
children
guidanc
first
line
treatment
low
risk
oseltamivir
resist
strain
zanamivir
inhal
diskhal
domin
strain
higher
risk
resist
eg
influenza
treatment
ideal
commenc
within
h
symptom
onset
patient
uncompl
influenza
patient
complic
influenza
defin
requir
hospit
admiss
andor
sign
lrti
central
nervou
system
involv
exacerb
underli
medic
condit
treatment
administ
regardless
time
onset
symptom
five
day
minimum
durat
treatment
may
continu
longer
depend
respons
second
line
treatment
indic
patient
poor
gastrointestin
absorpt
poor
clinic
respons
first
line
treatment
inhal
zanamivir
mg
twice
daili
adult
children
year
age
recommend
treatment
intraven
nebul
zanamivir
may
also
consid
patient
abl
use
inhal
zanamivir
effect
use
prepar
zanamivir
unlicens
avail
compassion
use
basi
name
patient
uk
patient
receiv
treatment
either
upper
lower
respiratori
tract
symptom
patient
suspect
complic
influenza
treatment
commenc
clinic
suspicion
without
wait
laboratori
confirm
similarli
event
increas
influenza
case
commun
patient
uncompl
infect
also
treat
first
sign
symptom
common
toxic
oseltamivir
nausea
vomit
rare
report
sever
advers
event
includ
anaphylaxi
hepat
dysfunct
http
last
access
june
dobson
et
al
zanamivir
occasion
associ
bronchospasm
patient
asthma
chronic
obstruct
pulmonari
diseas
http
last
access
june
williamson
pegram
new
agent
favipiravir
toyama
chemic
investig
antivir
drug
function
nucleotid
analogu
inhibitor
viral
rna
polymeras
furuta
et
al
shown
effect
oseltamivirresist
season
pandemicvirus
vitro
sleeman
et
al
recommend
current
public
health
england
guidanc
follow
manag
influenza
infect
ribavirin
known
effect
rna
virus
includ
rsv
drug
avail
aerosol
intraven
oral
use
time
write
access
aerosol
ribavirin
uk
limit
licens
product
longer
avail
altern
aerosol
product
manufactur
valeant
pharmaceut
quebec
canada
may
avail
centr
uk
unlicens
would
need
import
toxic
associ
administr
aerosol
ribavirin
includ
bronchospasm
cough
claustrophobia
nausea
rash
reduc
pulmonari
function
mucu
plug
conjunctiv
irrit
shah
chemali
potenti
risk
ribavirin
teratogen
mutagen
patient
staff
made
awar
risk
document
full
summari
product
characterist
http
last
access
april
intraven
ribavirin
associ
haemolysi
leucopenia
hyperbilirubinaemia
oral
ribavirin
associ
anaemia
nausea
shah
chemali
full
toxic
profil
oral
ribavirin
avail
summari
product
characterist
http
last
access
decemb
recent
adult
studi
compar
use
intermitt
versu
continu
aerosol
ribavirin
administr
found
statist
differ
progress
lrti
durat
viral
shed
two
regimen
chemali
et
al
avail
data
efficaci
aerosol
ribavirin
larg
limit
singl
centr
studi
boeckh
et
al
report
random
control
trial
aerosol
ribavirin
dose
g
time
daili
compar
support
care
posthsct
patient
upper
respiratori
tract
rsv
infect
patient
includ
children
includ
due
slow
accrual
period
end
point
develop
clinic
pneumonia
occur
ribavirin
recipi
control
patient
patient
aliv
followup
boeckh
et
al
recent
detail
review
shah
chemali
includ
random
control
trial
plu
prospect
studi
retrospect
studi
hsct
patient
receiv
aerosol
ribavirin
without
intraven
immunoglobulin
ivig
signific
reduct
progress
lrti
receiv
ribavirin
urti
stage
compar
compar
p
median
durat
therapi
vari
studi
usual
although
longer
sever
infect
shah
chemali
conclus
review
articl
reflect
recent
studi
adult
paediatr
allogen
transplant
patient
also
found
aerosol
ribavirin
urti
stage
import
singl
factor
reduc
progress
lrti
mortal
shah
et
al
retrospect
studi
review
outcom
patient
laboratoryconfirm
rsv
infect
januari
may
patient
treat
aerosol
ribavirin
andor
ivig
discret
treat
physician
group
subsequ
publish
immunodefici
score
index
base
data
patient
studi
present
urti
symptom
shah
et
al
patient
stratifi
low
medium
highrisk
group
base
score
system
see
tabl
iv
patient
score
classifi
lowrisk
score
classifi
moder
risk
score
classifi
highrisk
shah
et
al
highrisk
patient
significantli
risk
lrti
mortal
moder
lowrisk
patient
p
patient
highrisk
group
also
greatest
benefit
ribavirin
administ
urti
stage
score
system
yet
valid
prospect
cohort
patient
number
studi
investig
role
immunodulatori
agent
treatment
rsv
includ
use
ivig
monoclon
antibodi
rsv
specif
immunoglobulin
respigam
withdrawn
manufactur
march
longer
avail
use
palivizumab
human
antirsv
monoclon
antibodi
use
anim
model
ottolini
et
al
found
safe
use
hsct
recipi
small
phase
studi
larger
seri
adult
children
treat
palivizumab
follow
hsct
show
evid
improv
surviv
prevent
progress
lrti
de
fontbrun
et
al
although
random
data
exist
stem
cell
transplant
popul
random
data
support
use
palivizumab
prophylaxi
select
highrisk
children
impactrsv
studi
group
palivizumab
licens
indic
treatment
rsv
patient
haematolog
malign
posthsct
palivizumab
recommend
treatment
adult
rsv
infect
may
consid
children
shah
chemali
review
thirteen
studi
includ
posthsct
adult
treat
aerosol
ribavirin
plu
either
ivig
palivizumab
rsvspecif
ivig
similarli
risk
progress
lrti
lower
treat
urti
stage
compar
trend
toward
lower
rate
progress
lrti
recipi
dual
therapi
patient
receiv
aerosol
ribavirin
alon
compar
p
rsvspecif
mortal
rate
patient
lrti
significantli
lower
combin
group
tabl
iv
immunodefici
score
index
patient
respiratori
syncyti
viru
infect
postallogen
haematopoiet
stem
cell
transplant
shah
et
al
neutrophil
count
l
lymphocyt
count
l
age
year
myeloabl
condit
graftversushost
diseas
acutechron
corticosteroid
preengraftmentwithin
transplant
vs
p
shah
chemali
recommend
patient
undergon
allogen
transplant
risk
factor
progress
lrti
rsv
receiv
therapi
aerosol
ribavirin
ivig
aerosol
ribavirin
avail
oral
ribavirin
may
altern
author
note
ivig
may
avail
use
patient
due
demand
manag
guidelin
unit
kingdom
http
last
access
decemb
algorithm
treatment
outlin
fig
oral
ribavirin
view
recent
lack
avail
aerosol
ribavirin
consider
interest
use
oral
ribavirin
rsv
infect
hsct
recipi
oral
ribavirin
licens
treatment
respiratori
virus
use
sever
report
khanna
et
al
report
retrospect
review
adult
patient
rsv
urti
lrti
twentyfour
patient
undergon
allogen
hsct
twentyf
patient
receiv
treatment
oral
ribavirin
ivig
oral
ribavirin
plu
palivizumab
urti
lrti
oral
ribavirin
administ
load
dose
mg
kg
increas
mg
three
time
daili
day
mg
three
time
daili
day
four
patient
requir
mechan
ventil
receiv
iv
ribavirin
use
dose
regimen
rsvattribut
mortal
five
patient
develop
haemolysi
khanna
et
al
recent
studi
use
oral
ribavirin
adult
patient
rsv
infect
posthsct
casey
et
al
seven
patient
urti
lrti
patient
receiv
oral
ribavirin
dose
mgkgd
four
divid
dose
escal
depend
clinic
respons
total
dose
mgkgd
along
ivig
three
patient
die
rsvrelat
respiratori
infect
seven
patient
urti
progress
lrti
start
dose
mgkgd
six
subsequ
respond
higher
dose
median
durat
therapi
rang
patient
develop
haemolysi
marcelin
et
al
also
recent
report
use
oral
ribavirin
heterogen
patient
group
patient
includ
hsct
recipi
patient
die
rsv
infect
one
develop
haemolyt
anaemia
lactic
acidosi
anoth
develop
alter
mental
statu
marcelin
et
al
although
evid
limit
oral
ribavirin
appear
safe
costeffect
treatment
urti
hsct
recipi
start
dose
higher
mgkgd
eg
mgkgd
may
effect
casey
et
al
intraven
ribavirin
intraven
ribavirin
licens
treatment
respiratori
virus
also
use
sever
small
seri
shah
chemali
report
review
four
retrospect
studi
two
prospect
studi
use
oral
intraven
ribavirin
without
ivig
adult
patient
receiv
treatment
lrti
die
shah
chemali
limit
data
avail
patient
receiv
intraven
ribavirin
urti
stage
suggest
use
intraven
ribavirin
restrict
patient
requir
rsvspecif
therapi
unabl
receiv
oral
aerosol
ribavirin
intraven
ribavirin
may
help
patient
receiv
mechan
ventil
treatment
nonallogen
transplant
patient
rsv
infect
limit
evid
efficaci
treatment
rsv
patient
undergo
autolog
transplant
chemotherapi
treatment
anaissi
et
al
report
adult
undergo
chemotherapi
without
autolog
transplant
patient
screen
pretreat
larg
number
patient
patient
found
rsv
posit
patient
receiv
rsvspecif
treatment
signific
increas
seriou
respiratori
complic
patient
rsv
suggest
patient
undergo
chemotherapi
treatment
autolog
transplant
would
gener
requir
rsv
specif
therapi
decis
made
casebycas
basi
recommend
aerosol
ribavirin
administ
allogen
transplant
patient
lower
respiratori
tract
infect
respiratori
syncyti
viru
oral
ribavirin
may
altern
allogen
transplant
patient
lower
respiratori
tract
infect
rsv
aerosol
ribavirin
avail
recommend
intraven
immunoglobulin
administ
allogen
transplant
patient
respiratori
syncyti
viru
infect
recommend
aerosolizedor
ribavirin
administ
allogen
transplant
patient
upper
respiratori
tract
infect
respiratori
syncyti
viru
multipl
risk
factor
progress
lower
respiratori
tract
infect
patient
hmpv
requir
therapi
although
prolong
asymptomat
shed
may
occur
may
infect
control
issu
requir
confirm
neg
viral
pcr
discuss
clinic
virolog
prior
relax
infect
control
measur
urti
treat
evid
reduc
risk
lrti
occurr
lrti
assess
casebycas
basi
immunodefici
score
index
shah
et
al
may
use
howev
must
appreci
lrti
hmpv
adult
compar
rsv
influenza
associ
similar
complic
rate
includ
intens
care
unit
icu
admiss
mechan
ventil
length
hospit
length
stay
icu
jain
et
al
high
preval
previou
infect
popul
mean
rel
high
titr
hmpv
neutral
antibodi
found
pool
ivig
vitro
studi
shown
similar
efficaci
ivig
rsv
hmpv
wyde
et
al
ivig
dose
gkg
weekli
use
sever
case
studi
small
seri
treat
patient
hmpv
shachormeyouha
et
al
kitanovski
et
al
publish
studi
use
ribavirin
treat
hmpv
somewhat
inconclus
ribavirin
valid
treatment
option
select
highrisk
case
sever
case
studi
report
resolut
infect
patient
advanc
lrti
use
intraven
safdar
bonney
et
al
oral
egli
et
al
nebul
ribavirin
shahda
et
al
renaud
et
al
usual
combin
ivig
recent
seattl
group
publish
experi
treat
lrti
caus
hmpv
n
compar
outcom
rsv
lrti
n
mortal
similar
renaud
et
al
impact
outcom
use
nebul
ribavirin
ivig
import
limit
studi
addit
small
retrospect
seri
studi
popul
imbalanc
half
hmpv
patient
receiv
ivig
ribavirin
delay
time
start
ribavirin
treatment
hmpvtreat
group
patient
receiv
therapi
advanc
diseas
present
earlier
posttranspl
untreat
group
human
monoclon
antibodi
target
hmpv
fusion
show
promis
ulbrandt
et
al
hamelin
et
al
corti
et
al
candid
peptid
antivir
also
develop
deffrasn
et
al
howev
present
none
approach
commerci
avail
current
effect
vaccin
avail
present
uncertainti
role
ribavirin
hmpv
routin
recommend
may
use
select
highrisk
patient
discret
treat
physician
therapi
hpiv
infect
gener
support
togeth
respiratori
isol
given
corticosteroid
therapi
risk
factor
progress
lrti
reduct
steroid
dosag
appropri
feasibl
may
valid
approach
therapi
ison
proven
antivir
agent
exist
anecdot
report
suggest
role
ribavirin
whether
aerosol
oral
intraven
form
sparrelid
et
al
chakrabarti
et
al
dignan
et
al
stankova
et
al
shima
et
al
casey
et
al
howev
patient
diagnos
direct
fluoresc
antibodi
cultur
ribavirin
given
nebul
found
improv
viral
shed
surviv
hpivlrti
regardless
concurr
use
immunoglobulin
absenc
copathogen
ison
remain
uncertainti
use
ribavirin
hpiv
infect
may
consid
select
high
risk
patient
lrti
altern
antivir
agent
preclin
earli
phase
clinic
trial
develop
alymova
et
al
chen
et
al
barik
lu
vaccin
develop
ongo
sever
decad
number
live
attenu
vaccin
undergo
clinic
trial
unlik
directli
applic
immunosuppress
patient
may
prove
use
context
vaccin
household
contact
rubin
et
al
reduct
risk
initi
viral
infect
immunosuppress
may
reduc
risk
secondari
bacteria
fungal
infect
alymova
et
al
bosch
et
al
current
specif
treatment
avail
hrv
infect
capsidbind
agent
pleconaril
studi
picornavirusinfect
patient
specif
set
hsct
limit
effect
reduct
symptom
durat
observ
drug
ultim
acquir
viral
resist
detect
hayden
et
al
pevear
et
al
anoth
capsidbind
drug
evalu
phase
ii
studi
enrol
asthmasuffer
inhal
interferonb
similarli
investig
asthmat
neither
agent
yet
test
hsct
recipi
vaccin
hrv
remain
challeng
prospect
due
mainli
presenc
hrv
serotyp
recommend
support
care
use
manag
hrv
infect
due
insuffici
evid
support
specif
therapi
recent
studi
confirm
increas
posthsct
mortal
patient
hrv
infect
pretranspl
underli
need
research
better
intervent
hrv
infect
campbel
et
al
recommend
support
care
use
manag
rhinoviru
insuffici
evid
support
specif
treatment
treatment
ribavirin
recommend
patient
upper
respiratori
tract
infect
parainfluenza
metapneumoviru
recommend
diagnosi
respiratori
viral
infect
made
polymeras
chain
reaction
pcr
test
ii
diagnosi
upper
respiratori
tract
infect
made
upper
respiratori
tract
specimen
obtain
nasopharyng
aspir
wash
collect
nasal
throat
swab
iii
diagnosi
lower
respiratori
tract
infect
made
lower
respiratori
tract
specimen
eg
bronchoalveolar
lavag
tracheal
aspir
induc
sputum
possibl
iv
patient
assess
risk
factor
progress
lower
respiratori
tract
infect
prior
decid
treatment
plan
v
patient
undergo
treatment
haematolog
malign
haematopoiet
stem
cell
transplant
well
staff
care
household
contact
receiv
influenza
vaccin
annual
basi
vi
current
public
health
england
recommend
post
exposur
prophylaxi
influenza
infect
follow
vii
allogen
transplant
patient
undergo
treatment
haematolog
malign
respiratori
tract
symptom
isol
haematooncolog
patient
outpati
set
possibl
suggest
screen
patient
may
consid
event
outbreak
respiratori
viral
infect
recommend
allogen
transplant
patient
undergo
treatment
haematolog
malign
respiratori
viral
infect
isol
side
room
neutral
air
pressur
antechamb
undergo
inpati
treatment
recommend
patient
respiratori
virus
activ
screen
copathogen
includ
pneumocysti
jirovecii
ii
patient
respiratori
virus
monitor
sign
respiratori
failur
critic
care
team
involv
requir
iii
immunosuppress
reduc
possibl
patient
respiratori
virus
iv
patient
upper
lower
respiratori
tract
symptom
screen
respiratori
viral
infect
prior
commenc
therapi
v
consider
given
delay
cytotox
therapi
haematopoiet
stem
cell
transplant
patient
activ
respiratori
viral
infect
vi
current
public
health
england
guidanc
follow
manag
influenza
infect
vii
aerosol
ribavirin
administ
allogen
transplant
patient
lower
respiratori
tract
infect
respiratori
syncyti
viru
viii
oral
ribavirin
may
altern
allogen
transplant
patient
lower
respiratori
tract
infect
rsv
aerosol
ribavirin
avail
ix
intraven
immunoglobulin
administ
allogen
transplant
patient
respiratori
syncyti
viru
infect
x
aerosolizedor
ribavirin
administ
allogen
transplant
patient
upper
respiratori
tract
infect
respiratori
syncyti
viru
multipl
risk
factor
progress
lower
respiratori
tract
infect
xi
support
care
use
manag
rhinoviru
specif
treatment
treatment
ribavirin
recommend
patient
upper
respiratori
tract
infect
parainfluenza
metapneumoviru
advic
inform
guidelin
believ
true
accur
time
go
press
neither
author
british
societi
haematolog
british
societi
blood
marrow
transplant
uk
clinic
virolog
network
publish
accept
legal
respons
content
guidelin
